METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

THE PRESENT INVENTION CONCERNS COMPOUNDS OF FORMULA IN A PREFERABLE EMBODIMENT, X REPRESENTS O; R¹ REPRESENTS C?-?ALKYL;CYCLO C?-??ALKYL OR (CYCLOC?-??ALKYL)C?-?ALKYL, WHEREIN ONE OR MORE HYDROGEN ATOMS IN A C?-?ALKYL-MOIETY OR IN A CYCLOC?-??ALKYL-MOIETY OPTIONALLY MAY BE REPLACED BY C?-?ALKYLOXY, ARYL, HALO OR THIENYL; R² REPRESENTS HYDROGEN; HALO; C?-? ALKYL OR AMINO;R³ AND R? EACH INDEPENDENTLY REPRESENT HYDROGEN OR C?-? ALKYL;OR R² AND R³ MAY BE TAKEN TOGETHER TO FORM -R²-R³-, WHICH REPRESENTS A BIVALENT RADICAL OF FORMULA -Z?-CH?-CH?-CH?-OR -Z?-CH?-CH?- WITH Z? BEING O OR NR¹¹ WHEREIN R¹¹ IS C?-?ALKYL; AND WHEREIN EACH BIVALENT RADICAL IS OPTIONALLY SUBSTITUTED WITH C?-? ALKYL; OR R³ AND R? MAY BE TAKEN TOGETHER TO FORM A BIVALENT RADICAL OF FORMULA -CH?-CH?-CH?-CH?-;R?REPRESENTS HYDROGEN; Y REPRESENTS O; AND ARYL REPRESENTS PHENYL OPTIONALLY SUBSTITUED WITH HALO. THE INVENTION ALSO RELATES TO THE USE OF A COMPOUND ACCORDING TO THE INVENTION AS A MEDICAMENT AND IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING OR PREVENTING GLUTAMATE-INDUCED DISEASES OF THE CENTRAL NERVOUS SYSTEM, AS WELL AS FORMULATIONS COMPRISING SUCH A COMPOUND AND PROCESSES FOR PREPARING SUCH A COMPOUND.